'Cml cp' presentation slideshows

The Treatment Continuum for Patients with CML

611 views • 36 slides

Shah N et al. Proc ASH 2010;Abstract 206.

Dasatinib versus Imatinib in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) in the DASISION Trial: 18-Month Follow-Up. Shah N et al. Proc ASH 2010;Abstract 206. DASISION Study Schema. Dasatinib 100mg PO QD (n = 259). R. Imatinib 400mg PO QD

373 views • 12 slides

1 Jain P et al. Proc ASH 2012;Abstract 70. 2 Jain P et al. Blood 2013;[Epub ahead of print].

211 views • 10 slides

Cortes JE et al. Proc ASH 2012; Abstract 163.

A Pivotal Phase 2 Trial of Ponatinib in Patients with CML and Ph + ALL Resistant or Intolerant to Dasatinib or Nilotinib , or with the T315I BCR?ABL Mutation: 12?Month Follow ?Up of the PACE Trial. Cortes JE et al. Proc ASH 2012; Abstract 163. Background.

358 views • 9 slides

Cortes JE et al. Proc ASH 2013;Abstract 1483.

Ponatinib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Cortes JE et al. Proc ASH 2013;Abstract 1483. Background.

287 views • 9 slides

Cortes JE et al. Proc ASH 2012; Abstract 163.

A Pivotal Phase 2 Trial of Ponatinib in Patients with CML and Ph + ALL Resistant or Intolerant to Dasatinib or Nilotinib , or with the T315I BCR?ABL Mutation: 12?Month Follow ?Up of the PACE Trial. Cortes JE et al. Proc ASH 2012; Abstract 163. Background.

313 views • 9 slides

Cortes JE et al. Proc ASH 2012; Abstract 3779.

Bosutinib as Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib : 36-Month Minimum Follow-Up Update. Cortes JE et al. Proc ASH 2012; Abstract 3779. Background.

328 views • 8 slides

Kantarjian H et al. Proc ASCO 2011;Abstract 6510.

Dasatinib or Imatinib (IM) in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Two-Year Follow-Up from DASISION. Kantarjian H et al. Proc ASCO 2011;Abstract 6510. DASISION Study Design. Dasatinib 100 mg QD (n = 259). R. Follow-up. 5 yrs. Imatinib 400 mg QD (n = 260).

252 views • 8 slides

Kantarjian H et al. Proc ASCO 2010;Abstract LBA6500. Kantarjian H et al.

Dasatinib Compared to Imatinib in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase (CML-CP): Twelve-Month Efficacy and Safety from the Phase III DASISION Study. Kantarjian H et al. Proc ASCO 2010;Abstract LBA6500. Kantarjian H et al.

318 views • 7 slides